Quick View
| Metric | Current Period | Same Period Previous Year | YoY |
|---|---|---|---|
| Revenue | ¥1010.2B | ¥964.6B | +4.7% |
| Operating Income | ¥110.3B | ¥113.1B | −2.4% |
| Ordinary Income | ¥141.8B | ¥141.9B | −0.1% |
| Net Income | ¥104.9B | ¥109.3B | −4.0% |
| ROE | 4.9% | 4.9% | - |
Executive Summary
Cumulative results for Q3 of the fiscal year ending March 2026 showed higher revenue but lower profit, with the key issue being declining profitability as revenue growth failed to translate into earnings growth. Revenue was ¥1,010.2B (up +4.7% YoY), Operating Income was ¥110.3B (down △2.4%), Ordinary Income was ¥141.8B (down △0.1%), and Net Income was ¥104.9B (down △4.0%). While deteriorating profitability in the core Chemicals Business pushed down Operating Income, non-operating income and extraordinary income supported Ordinary Income and Income Before Taxes.
Factors Affecting Performance
【Revenue】Revenue was ¥1,010.2B, up +4.7% YoY. By segment, Chemicals was ¥449.4B (44.5% composition ratio, up +1.7% YoY), Processing was ¥362.2B (35.9% composition ratio, +1.8%), and Equipment was ¥190.4B (18.8% composition ratio, +18.8%), with the Equipment Business driving company-wide revenue growth.
【Profit and Loss】Operating Income was ¥110.3B, down △2.4% YoY, while the Operating Margin declined to 10.9% from 11.7% in the previous year. The primary factor was a decline in the Chemicals Business segment profit margin from 18.0% to 15.9%, reducing segment profit in that business to ¥71.5B (down △10.2% YoY). The Equipment Business improved its profit margin from 2.5% to 6.5%, generating profit of ¥12.5B (more than 3.1 times the previous year); however, its scale was insufficient to fully offset the decline in Chemicals Business profit. Ordinary Income of ¥141.8B (down △0.1%) reflected the mitigation of the decline at the operating level by ¥38.0B in non-operating income, including ¥7.2B in dividends received and ¥8.5B in equity-method gains and losses. Extraordinary income of ¥0.64B, primarily consisting of ¥5.9B in gains on sales of investment securities, was recorded, resulting in Income Before Taxes of ¥145.5B (up +2.4%); however, Net Income remained at ¥104.9B (down △4.0%) after accounting for profit attributable to non-controlling interests and other items. Overall, the Company posted higher revenue but lower profit.
Segment Analysis
The Chemicals Business remains the largest source of profit, with revenue of ¥449.4B (44.5% composition ratio) and a profit margin of 15.9%; however, the margin declined from 18.0% in the previous year, weighing on company-wide profit. The Equipment Business recorded revenue of ¥190.4B but achieved a significant improvement in its profit margin to 6.5%, strengthening its role as a growth driver with profit growth of more than 3.1 times. The Processing Business remained broadly flat, with revenue of ¥362.2B and a profit margin of 10.2% (10.4% in the previous year). Company-wide expenses were ¥12.8B, up +11.8% YoY, exceeding the revenue growth rate of +4.7%; rising indirect costs could offset the benefits of improved profitability in the Chemicals Business.
Key Financial Indicators
【Profitability】The Operating Margin was 10.9%, down approximately 0.8pt from 11.7% in the same period of the previous year, while the Net Profit Margin also declined by approximately 0.6pt to approximately 9.3%. The Gross Margin was broadly flat at 33.7% (33.5% in the previous year). 【Cash Quality】The Company holds substantial financial assets, including ¥636.4B in cash and deposits and ¥426.4B in investment securities. Interest-bearing debt consists solely of ¥2.5B in long-term borrowings, indicating an extremely conservative financial structure. 【Capital Efficiency】ROE was 4.9% (approximately 4.4% on an annualized basis), with the earnings level subdued relative to net assets of ¥2,143.9B. Total asset turnover remains low, and cash and investment securities accounting for approximately 40% of total assets is a factor suppressing asset efficiency. 【Financial Soundness】The Equity Ratio was 82.7% and the Current Ratio was 382.2%, indicating a strong short-term liquidity position and capital base.
Cash Flow Analysis
Although the Company does not disclose a cash flow statement, cash trends can be assessed from changes in the balance sheet. Cash and deposits declined to ¥636.4B from ¥778.1B in the same period of the previous year, while investment securities increased from ¥426.4B to a level equivalent to ¥344.8B. Interest-bearing debt consists solely of ¥2.5B in long-term borrowings, and the Company maintains a low debt-to-equity ratio of approximately 0.1%, indicating extremely limited dependence on external financing. Treasury stock increased to ¥241.2B, suggesting that the use of funds through shareholder returns and capital policies may have contributed to the decline in the cash balance.
Quality of Earnings
Ordinary Income of ¥141.8B exceeded Operating Income of ¥110.3B by ¥31.5B, with the difference attributable to ¥38.0B in non-operating income, including ¥7.2B in dividends received, ¥6.8B in interest received, and ¥8.5B in equity-method gains and losses. In addition, Income Before Taxes of ¥145.5B benefited from ¥6.4B in extraordinary income, primarily consisting of ¥5.9B in gains on sales of investment securities; this should be distinguished from recurring business profitability as a temporary factor. Net extraordinary gains and losses amounted to ¥3.7B and made a certain contribution to profit attributable to owners of the parent. Accordingly, it should be noted that a portion of Net Income includes non-recurring factors. Comprehensive Income was ¥139.5B, exceeding Net Income of ¥104.9B, mainly due to an increase of ¥57.5B in valuation difference on other securities. However, foreign currency translation adjustments made a negative contribution of △¥18.0B, and these factors should be evaluated separately from the Company’s underlying business earnings power.
Earnings Forecast and Guidance
Progress against the full-year company plan was 77.1% for Revenue, 78.8% for Operating Income, and 76.7% for Ordinary Income, all exceeding the standard progress benchmark of 75%. However, the full-year plan itself assumes declines of △1.0% in Revenue, △6.7% in Operating Income, and △7.2% in Ordinary Income from the previous year, indicating that conservative assumptions have been incorporated for Q4. While the high progress rates indicate steady achievement toward the targets, the full-year plan is based on a declining earnings trend; therefore, profitability trends in Q4 will determine the assessment following achievement of the full-year plan.
Shareholder Returns
The Q2 dividend was ¥25.00 per share, and the full-year forecast dividend is ¥50.00, with equal interim and year-end distributions planned. The forecast Payout Ratio against forecast full-year Net Income of ¥120.0B is approximately 46.3%, a level that appears sustainable from an earnings perspective when assessed solely on the basis of dividends. The near-net-cash financial structure, with cash and deposits of ¥636.4B and interest-bearing debt of ¥2.5B, supports flexibility in dividend payments. The Company holds ¥241.2B in treasury stock (9.3% of total assets); however, the acquisition amount for the current period cannot be identified from the disclosed information, so the Total Return Ratio, combining dividends and share repurchases, is not evaluated.
Risk Factors
-
Deteriorating profitability in the core Chemicals Business: The Chemicals Business, the largest segment with revenue of ¥449.4B, saw its segment profit margin decline from 18.0% to 15.9%, while profit decreased △10.2% YoY. Depending on the progress of price pass-through and raw material costs, this could affect the pace of recovery in company-wide Operating Income.
-
Extension of the accounts receivable collection period: Accounts receivable and notes receivable amounted to ¥426.4B, and GPT analysis indicates annualized DSO of 116 days. Longer collection terms could lead to increased working capital requirements and heightened credit risk.
-
Market price volatility risk relating to investment securities: Investment securities amounted to ¥426.4B, representing 16.5% of total assets. Valuation difference on other securities increased by ¥57.5B during the current period, but fluctuations in the equity markets could affect net assets and Comprehensive Income.
Industry Benchmark (For Reference; Compiled by the Company)
Profitability and Return
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Margin | 10.9% | 8.6% (4.3%–12.7%) | +2.3pt |
| Net Profit Margin | 10.4% | 6.4% (2.8%–10.3%) | +4.0pt |
Profitability exceeds the industry median, and the Company maintains relatively high margins even within the manufacturing sector.
Growth and Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth Rate (YoY) | 4.7% | 3.3% (-2.1%–8.9%) | +1.4pt |
The Revenue Growth Rate also exceeds the industry median and is positioned toward the upper portion of the IQR.
※Source: Compiled by the Company
Key Points from the Earnings Results
-
Despite higher revenue, the Operating Margin declined by approximately 0.8pt year on year, making the recovery of margins in the core Chemicals Business, rather than revenue growth, the primary focus for evaluating profitability.
-
The Equipment Business improved significantly in both revenue and profit margin. Although its 6.5% profit margin remains below that of the Chemicals Business (15.9%), its increasing contribution as a growth driver is evident.
-
The conservative financial base, comprising an Equity Ratio of 82.7%, a Current Ratio of 382.2%, and interest-bearing debt of ¥2.5B, enhances resilience to changes in the external environment. However, there remains room for improvement in asset efficiency, and profitability trends going forward will be closely monitored together with progress toward achieving the full-year plan.
Theoretical Share Price (Reference Value)
| Scenario | Theoretical Share Price |
|---|---|
| bear | ¥1,608 |
| base | ¥1,636 |
| bull | ¥1,659 |
| Calculation Assumption | Value |
|---|---|
| Book Value per Share (BPS) | ¥1,788 |
| Adjusted Forecast EPS | ¥119.2 |
| Cost of Equity r | 9.77% (10-year government bond 2.77% + equity risk premium 6.00% + size premium 1.00%) |
| Persistence Factor of Residual Income ω / Explicit Forecast Period | 0.62 / 5 years |
| Assumed Payout Ratio | 45.1% |
| Forecast EPS Confidence Adjustment | ×1.075 (based on the track record of guidance achievement rates in the same industry) |
| Implied PBR / PER | 0.91x / 13.7x |
Sensitivity: ¥1,592–¥1,683 at ±1% in the cost of equity, and ¥1,631–¥1,639 at ω±0.1.
Notes:
- Because forecast ROE is below the cost of equity, the theoretical value is below Book Value per Share.
- Net assets as of the quarter-end are used (there is a timing difference from the full-year forecast).
(Calculation model: Residual Income Model (Ohlson-type; explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee future share prices.)
This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting a professional advisor as necessary.
---End of Report---
AI Financial Analysis
Executive Summary
FY2026 Q3 performance was resilient at the sales level but exhibited modest operating-profit pressure, while the balance sheet remained exceptionally strong. Revenue increased 4.7% year on year to ¥101.02bn. Gross profit rose to ¥34.01bn, and the gross margin edged up 12bp to 33.7%. Operating income nevertheless declined 2.4% to ¥11.04bn. The operating margin compressed by 80bp to 10.9% from 11.7%, reflecting SG&A growth of 9.1%, materially above revenue growth. Ordinary income was broadly flat at ¥14.18bn, supported by a substantial ¥3.80bn of non-operating income. Interest income of ¥0.68bn and dividend income of ¥0.72bn demonstrate the earnings contribution from the company’s large liquidity and investment portfolio. Profit attributable to owners of parent declined 1.9% to ¥9.37bn, equivalent to a 9.3% net margin. Reported annualized ROE was 5.8%, below the 8% level generally viewed as a minimum attractive return threshold. The Chemicals business remained the core earnings engine, although its segment profit declined materially. Equipment delivered the strongest improvement, with both revenue and profitability expanding sharply. Processing revenue grew but segment profit was slightly lower, indicating limited operating leverage in that operation. Profit before tax increased 2.4% to ¥14.55bn, aided by ¥0.64bn of extraordinary income, principally a ¥0.59bn gain on sales of investment securities. Consequently, the decline in parent profit was contained but underlying operating earnings were weaker than the headline revenue trend. The company’s financial position is a material mitigant, with ¥63.64bn of cash and deposits against only ¥0.25bn of interest-bearing debt. Full-year guidance implies a broadly normal Q4 run rate, with the Q3 cumulative progress rate slightly ahead of the standard 75% level across sales and profit measures. The principal operating issue for investors is whether Chemicals margin can recover while the company controls the pace of SG&A growth and improves collection efficiency.
Profitability Analysis
The reported annualized DuPont ROE is 5.8%, decomposed into a 9.3% net profit margin, 0.520x annualized asset turnover, and 1.21x financial leverage. Low financial leverage is intentional and consistent with the company’s net-cash balance sheet; it is not a credit concern, but it limits the leverage contribution to shareholder returns. The largest profitability change in the period was the 80bp contraction in operating margin to 10.9%, despite a 12bp improvement in gross margin to 33.7%. This identifies SG&A as the principal source of margin pressure: SG&A increased 9.1% year on year to ¥22.97bn, versus 4.7% revenue growth. Chemicals is the core business by segment profit contribution, generating ¥7.15bn, or approximately 59% of segment profit before corporate costs. Chemicals revenue increased 1.7% to ¥43.99bn, but segment profit fell 10.2% to ¥7.15bn and its margin declined 217bp to 16.3%. Equipment was the clear positive outlier: revenue increased 18.8% to ¥18.56bn, segment profit rose 214.1% to ¥1.25bn, and margin expanded 418bp to 6.7%. Processing revenue rose 1.8% to ¥36.17bn, while segment profit declined 0.6% to ¥3.68bn, leaving margin broadly stable at 10.2%. Other operations generated revenue of ¥2.31bn but recorded a ¥0.04bn segment loss. Unallocated corporate costs increased to ¥1.28bn from ¥1.14bn, further constraining reported operating income. The tax burden was 0.644, consistent with a 27.9% effective tax rate, while the interest burden exceeded 1.0x because non-operating income substantially exceeded interest expense. Interest coverage of 848.9x confirms that debt servicing has no material bearing on profitability.
Growth Assessment
Revenue growth of 4.7% was broad-based, led by Equipment, but the quality of growth was mixed because consolidated operating income fell 2.4%. Equipment’s 18.8% sales expansion and substantial profit recovery provide an encouraging source of incremental growth. In contrast, the 10.2% decline in Chemicals segment profit despite sales growth indicates that the core business faced cost, pricing, mix, or operating-expense pressure. Processing continued to grow modestly, but its slightly lower segment profit shows limited conversion of incremental sales into earnings. The full-year forecast calls for revenue of ¥131.00bn, operating income of ¥14.00bn, ordinary income of ¥18.50bn, and parent profit of ¥12.00bn. Q3 cumulative progress is 77.1% for revenue, 78.8% for operating income, 76.7% for ordinary income, and 78.1% for parent profit, compared with a standard 75% Q3 progress rate. The modestly above-standard progress suggests that guidance is achievable without requiring an unusually strong final quarter. Implied Q4 results are approximately ¥29.98bn of revenue, ¥2.97bn of operating income, ¥4.32bn of ordinary income, and ¥2.63bn of parent profit. Full-year guidance nevertheless implies a year-on-year decline of 6.7% in operating income and 7.2% in ordinary income, so management is not forecasting a near-term restoration of prior-period profitability. Investment income remains meaningful to ordinary earnings, including ¥0.85bn in equity-method earnings, ¥0.72bn in dividends, and ¥0.68bn in interest income. The company’s chemical-treatment and surface-processing exposure creates sensitivity to manufacturing activity, customer production volumes, input costs, and industrial capital spending. Sustained growth therefore depends on improved Chemicals earnings conversion and continued normalization of Equipment profitability rather than sales growth alone.
Financial Health
Financial health is exceptionally robust. The current ratio of 382.2% and quick ratio of 370.0% are far above conventional liquidity thresholds, with working capital of ¥88.16bn. Current assets of ¥119.39bn exceed current liabilities of ¥31.23bn by a wide margin, indicating no maturity mismatch risk. Cash and deposits total ¥63.64bn, compared with only ¥0.25bn of interest-bearing debt, resulting in net cash of approximately ¥63.39bn. Debt-to-equity is only 0.21x and debt-to-capital is 0.1%, while interest coverage is 848.9x. Total liabilities represent only 17.3% of total assets, and the capital adequacy ratio improved to 74.9% from 73.0%. Investment securities increased by ¥8.16bn year on year to ¥42.64bn and represent 16.5% of total assets, increasing sensitivity of comprehensive income and equity to market-price movements. Cash and deposits declined by ¥14.16bn year on year, while total assets declined by ¥8.14bn to ¥259.11bn. Treasury stock increased in absolute negative balance by ¥8.17bn to negative ¥24.12bn, a 51.3% year-on-year change, consistent with significant capital-return activity. This reduces outstanding equity capital and can support per-share metrics, but it also explains part of the reduction in total equity to ¥214.39bn from ¥223.30bn. Construction in progress rose by ¥2.49bn to ¥5.14bn, indicating an active investment pipeline; it is 7.1% of PPE and does not indicate an unusually concentrated construction risk. Defined-benefit obligations include a ¥3.63bn net defined-benefit liability, which is readily manageable relative to the group’s liquidity and equity base.
Notable B/S Changes
Cash and deposits: -¥14.16bn year on year to ¥63.64bn - liquidity remains very strong, but the decline should be assessed alongside capital returns and investment deployment. Investment securities: +¥8.16bn year on year to ¥42.64bn - a larger investment portfolio supports dividend and interest income but increases exposure to market-value movements. Treasury stock: -¥8.17bn year on year to -¥24.12bn (-51.3%) - substantial treasury-share accumulation supports per-share capital management but reduces reported equity. Construction in progress: +¥2.49bn year on year to ¥5.14bn (+93.8%) - indicates an expanding investment pipeline and warrants monitoring for execution and return discipline.
Cash Flow Quality
Profit quality at the operating level is moderated by the divergence between revenue growth and operating-income decline. Ordinary income of ¥14.18bn exceeded operating income by ¥3.15bn, driven largely by non-operating investment-related income rather than core operations. Non-operating income represented 3.8% of revenue and included ¥0.72bn of dividend income, ¥0.68bn of interest income, ¥0.85bn of equity-method earnings, and ¥0.19bn of foreign-exchange gains. Profit before tax also benefited from net extraordinary income of ¥0.37bn, principally the ¥0.59bn gain on sales of investment securities, partly offset by ¥0.28bn of extraordinary losses. The securities-sale gain equals approximately 6.3% of parent profit and is supportive but not central to earnings. The gap between ordinary income and parent profit was 33.9%, principally reflecting ¥4.06bn of income tax expense and ¥1.11bn attributable to non-controlling interests, partly offset by net extraordinary gains. Working-capital discipline requires close attention: the quality alert identifies annualized DSO of 116 days, well above the 60-day warning threshold. The root cause is a relatively large trade-receivable balance of ¥42.64bn, equal to 16.5% of total assets. This collection period is long for a manufacturing-oriented group and can delay conversion of reported sales and profits into cash. Receivables did decline by ¥1.88bn year on year, which is directionally constructive, but the reported DSO remains elevated because the collection cycle is still lengthy. The investment implication is that investors should monitor whether receivable days normalize alongside revenue growth, as persistently slow collections could weaken cash conversion and raise counterparty exposure.
Dividend Sustainability
The company paid an interim dividend of ¥25.00 per share and forecasts a full-year dividend of ¥50.00 per share. Based on forecast EPS of ¥110.86, the implied full-year dividend payout ratio is approximately 45.1%, within the sub-60% range generally considered sustainable. The interim payout ratio calculated from the disclosed Q2 dividend was 35.4%. The large net-cash position, negligible interest-bearing debt, and substantial retained earnings of ¥175.19bn provide a strong balance-sheet foundation for the dividend. Treasury stock increased by ¥8.17bn year on year, indicating that buybacks or other treasury-share transactions have also been material to capital allocation. Accordingly, aggregate shareholder distributions should be assessed using a total return ratio rather than the dividend payout ratio alone. The planned dividend appears well supported by earnings capacity and financial resources, while the scale and recurrence of treasury-share activity should remain an important capital-allocation monitor.
Risk Assessment
Business risks include Core Chemicals segment profit declined 10.2% to ¥7.15bn despite 1.7% revenue growth, with margin falling 217bp to 16.3%; a prolonged inability to pass through cost inflation or improve mix would weigh on group earnings., The group is exposed to industrial production cycles, customer capital expenditure, automotive and general-manufacturing demand, and chemical-input cost volatility., Equipment’s profit recovery is strong but starts from a low prior-year base; sustaining the 6.7% segment margin will be important to validate the improvement., Annualized DSO of 116 days is the principal operating-quality alert. The long collection cycle may reflect customer terms or project-related billing practices, and it heightens the importance of customer-credit management..
Financial risks include Investment securities of ¥42.64bn, or 16.5% of total assets, expose equity and comprehensive income to market valuation changes., Cash declined ¥14.16bn year on year and treasury stock expanded by ¥8.17bn; continued large capital returns could reduce financial flexibility if not matched by earnings and cash generation., Non-operating income is material at ¥3.80bn, making ordinary income partly sensitive to interest income, dividends, equity-method performance, foreign exchange, and investment-market conditions..
Key concerns include SG&A increased 9.1%, almost twice the 4.7% revenue growth rate, causing operating-margin compression despite an improved gross margin., Reported annualized ROE of 5.8% remains below the 8% benchmark, with low asset turnover and a large surplus-capital position limiting returns., Full-year guidance anticipates operating-income and ordinary-income declines, indicating that management does not yet expect a full recovery in underlying profitability., The ¥0.59bn gain on sales of investment securities supported pre-tax profit; recurring operating progress should be evaluated separately from these gains..
Investment Implications
Key takeaways include Sales momentum is positive, but operating leverage was negative because SG&A growth outpaced revenue growth., Chemicals remains the core profit contributor and therefore the central determinant of a recovery in group operating earnings., Equipment is the principal positive earnings inflection, with segment margin improving to 6.7% from 2.5%., The balance sheet is a major strategic strength, combining ¥63.64bn of cash with only ¥0.25bn of interest-bearing debt., The forecast dividend of ¥50.00 per share implies a moderate 45.1% payout ratio based on forecast EPS..
Metrics to watch include Chemicals segment margin and its ability to recover from 16.3%, Consolidated SG&A growth relative to revenue growth, Annualized DSO, currently 116 days, and the trade-receivables balance, Equipment segment margin sustainability following the sharp recovery, Investment securities valuation and associated comprehensive-income volatility, Scale of treasury-share transactions relative to earnings and cash resources, Achievement of full-year operating-income guidance of ¥14.00bn.
Regarding relative positioning, The company combines a good 10.9% operating margin, a 9.3% net margin, and unusually conservative leverage with substantial liquidity. Its relative weakness is capital efficiency, as annualized ROE of 5.8% is held back by low asset turnover and a large equity base. Operationally, the group is positioned more defensively than highly leveraged manufacturing peers, but its earnings profile currently depends on restoring margin in its core Chemicals business and reducing the gap between revenue growth and operating-profit growth.